Rhythm Pharmaceuticals (RYTM) announced that it reacquired the rights to Imcivree in China, including mainland China, Hong Kong and Macau, as the company agreed to terminate its 2021 licensing agreement with RareStone Group. Under the agreement, Rhythm has agreed to repay $6.3M in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no additional consideration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- 3 Best Stocks to Buy Now, 3/20/2025, According to Top Analysts
- Rhythm Pharmaceuticals gets orphan drug designation for setmelanotide in Japan
- Buy Rating for Rhythm Pharmaceuticals: Setmelanotide’s Potential in Addressing Unmet Needs in Hypothalamic Obesity
- Rhythm Pharmaceuticals: Buy Rating on Promising Setmelanotide Phase 3 Data for Hypothalamic Obesity
- Citizens JMP pharmaceuticals analysts hold analyst/industry conference call